Back to Acceleration Radar
EXELExelixis Inc
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · Large
$64.53−1.19%
As of 23 Oct 2026Mkt cap $14.5B
Stage 13
WAIT
Fundamentals
47.9/75
Technical
5.0/15
Independent
52.9/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +11.4%
- 3M
- +15.6%
- 6M
- +43.6%
- 1Y
- +78.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 20.3xHist median 17.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 15.5x
- FCF yield
- 6.4%
Quality
- ROIC
- —
- Operating margin
- 27.9%
- FCF margin
- 37.7%
- Current ratio
- 3.6x
Growth
- Revenue growth
- +7.0%Latest FY YoY
- Revenue CAGR
- +12.8%
- EPS CAGR
- +40.2%
- FCF CAGR
- +26.1%
Capital
- Share-count trend
- −6.4%3Y annualised
- Net cash
- $282M-0.3x OCF
Annual trend
- CAGR 2021–2025
- +12.8%
- Latest · 2025
- $2B
- YoY
- +7.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded